|
1）Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. Collaborators KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009; 113: S1-130
|
|
|
|
2）Massry S. K/DOQI Clinical Practice Guidelines. Am J Kidney Dis. 2003; 42 (Suppl3): S1-201
|
|
|
|
|
|
3）日本透析医学会. 透析患者における二次性副甲状腺機能亢進症治療ガイドライン. 透析会誌. 2006; 39: 1435-55
|
|
|
|
|
|
4）Payne RB, Little AJ, Williams RB, et al. Interpretation of serum calcium levels in patients with abnormal serum proteins. Br Med J. 1973; 4: 643-6
|
|
|
|
|
|
5）Yokoyama K, Katot N, Kubo H, et al. Clinical significance of the K/DOQI bone guidelines in Japan. Am J Kidney Dis. 2004; 44: 383-4
|
|
|
|
|
6）Fukagawa M, Yumita S, Akizawa T, et al. KRN1493 study group: Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant. 2008; 23: 328-35
|
|
|
|
|
|
7）Ohashi N, Uematsu T, Nagashima S, et al. The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis. Br J Clin Pharmacol. 2004; 57: 726-34
|
|
|
|
|
|
8）Shoji T, Shinohara K, Kimoto E, et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant. 2004; 19: 179-84
|
|
|
|
|
|
9）Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol. 2005; 16: 1115-25
|
|
|
|
|
|
10）Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006; 70: 771-80
|
|
|
|
|
|
11）Tentori F, Hunt WC, Stidley CA, et al. Medical Directors of Dialysis Clinic Inc: Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006; 70: 1858-65
|
|
|
|
|
|
12）Kovesdy CP, Ahmadzadeh S, Anderson JE, et al. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med. 2008; 168: 397-403
|
|
|
|
|
|
13）Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J, et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int. 2008; 74: 1070-8
|
|
|
|
|
|
14）Fukagawa M, Komaba H, Onishi Y, et al. MBD-5D Study Group. Mineral metabolism management in hemodialysis patients with secondary hyperparathyroidism in Japan: baseline data from the MBD-5D. Am J Nephrol. 2011; 33: 427-37
|
|
|
|
|
|
15）Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15: 2208-18
|
|
|
|
|
|
16）Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005; 67: 1179-87
|
|
|
|
|
|
17）Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1,3, and 4 study. J Am Soc Nephrol. 2005; 16: 1788-93
|
|
|
|
|
|
18）Kimata N, Albert JM, Akiba T, et al. Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: the Japan dialysis outcomes and practice patterns study. Hemodial Int. 2007; 11: 340-8
|
|
|
|
|
|
19）Theodorou DJ, Theodorou SJ, Resnick D. Imaging in dialysis spondyloarthropathy. Semin Dial. 2002; 15: 290-6
|
|
|
|
|
|
20）Abe T, Uchita K, Orita H, et al. Effect of beta(2)-microglobulin adsorption column on dialysis-related amyloidosis. Kidney Int. 2003; 64: 1522-8
|
|
|
|
|
|
21）Kazama JJ, Maruyama H, Gejyo F. Reduction of circulating beta2-microglobulin level for the treatment of dialysis-related amyloidosis. Nephrol Dial Transplant. 2001; 16 (Suppl 4): 31-5
|
|
|
|
|
|
22）Yamamoto H, Kasai K, Hamada C, et al. Japan Peritoneal Dialysis-Mineral Bone Disorders (PD-MBD) Research Group. Differences in corrective mode for divalent ions and parathyroid hormone between standard- and low-calcium dialysate in patients on continuous ambulatory peritoneal dialysis―result of a nationwide survey in Japan. Perit Dial Int. 2008; 28 (Suppl 3): S128-30
|
|
|
|
|
|
23）Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol. 2005; 16(3): 800-7. Epub 2005 Feb 2
|
|
|
|
|
|
24）骨粗鬆症の予防と治療ガイドライン作成委員会, 編.骨粗鬆症の予防と治療ガイドライン（2006年版）.東京: ライフサイエンス出版; 2006
|
|
|
|
|
|
25）Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000; 342: 1478-83
|
|
|
|
|
|
26）Schroff RC, Donald AE, Hiorns MP, et al. Mineral metabolism and vascular damage in children on dialysis. J Am Soc Nephrol. 2007; 18: 2996-3003
|
|
|
|
|